Company Overview

Incorporated in 1985, Ambey Laboratories Ltd is a specialized manufacturer within India's growing agrochemical sector, focusing on providing essential chemical solutions for crop protection. Originally established as "Ambey Laboratories Private Limited" on March 20, 1985, it transitioned to a Public Limited Company, "Ambey Laboratories Limited," on December 30, 2014. Founded by Mr. Anil Kumar Gupta and Mr. Kewal Sehgal, the company has nearly four decades of operational experience, establishing itself as a reliable player in the Indian chemical industry.

Business Operations and Products

Ambey Laboratories specializes in the manufacturing and supply of high-quality "2, 4-D base chemicals," adhering to stringent Environmental, Health, and Safety (EHS) standards. The company's product portfolio includes various formulations of 2,4-D chemicals, widely used as herbicides in agriculture.

Key products manufactured include:

- 2,4-D Amine Salt (available in 480 gm/L, 625 gm/L, 720 gm/L, 806 gm/L, 840 gm/L, 866 gm/L concentrations)

- 2,4-D Acid Tech (98% min)

- 2,4-D Ethyl Ester Tech (95% min)

- 2,4-D 2-Ethylhexyl Ester Tech (96% min)

- 2,4-D Sodium Salt (95% min)

- Hexaconazole (5% min)

These products are designed to meet diverse agricultural needs and application methods. The company's manufacturing facility in Behror, Rajasthan, is certified with ISO 9001:2015, underscoring its commitment to international quality standards.

Financial Performance

- Market Capitalization: ₹99.79 Cr (as of 29th May 2025). The company is classified as a Small Cap entity.

- Recent Financial Highlights (FY 2024):

- Total Revenue: Approximately ₹131.27 Cr.

- Profit: ₹4.78 Cr.

- Key Financial Metrics (Recent Data):

- Stock P/E: 19.8

- Book Value: ₹30.6

- ROCE: 9.62%

- ROE: 8.86%

- Face Value: ₹10.0

- Trailing Twelve Months (TTM) Performance:

- Operating Revenue: ₹312.24 Cr

- Annual Revenue Growth: 9% (good)

- Pre-tax Margin: 5% (okay)

- ROE: 6% (fair, needs improvement)

- Balance Sheet: Debt to Equity ratio of 14% indicates a healthy balance sheet.

Recent Corporate Developments

- Debt Management: On 3rd July 2025, Ambey Laboratories fully prepaid and redeemed unlisted NCDs totaling ₹53.1 crore before maturity, showcasing a strong focus on debt reduction and financial optimization.

- Capital Raising: On 2nd July 2025, an EGM was scheduled to approve an increase in authorized capital to ₹37 Cr and a preferential issue of 1.08 Cr warrants worth ₹50 Cr, signaling potential expansion plans and capital infusion.

Shareholding Pattern

- Promoter Holding: Sarina Gupta and Rishita Gupta collectively own 69.89% of the total equity. This substantial promoter holding reflects strong management confidence and alignment with shareholder interests.

- Pledging: There is no promoter pledging of shares, indicating a healthy and unencumbered promoter stake.

Market Performance and Trading

- 52-Week High: ₹97.20

- 52-Week Low: ₹36.35

- Past Year Return: -55.18%

The stock has experienced significant volatility, influenced by market conditions and company-specific factors. Despite short-term challenges, the company maintains its operations and market position in the agrochemical sector.

Industry Position and Outlook

Ambey Laboratories Ltd operates in the Materials sector, specifically within the Specialty Chemicals sub-sector, focusing on agrochemicals essential for India's agricultural productivity.

- Major Competitors: Crop Life Science, Aimco Pesticide, Aristo Bio-Tech&Lis, Bhaskar Agrochem, Super Crop Safe, Sikko Industries, Phyto Chem (India).

- Industry Trends: The Indian agrochemical industry is driven by the growing emphasis on agricultural productivity and food security. As a specialized manufacturer of 2,4-D chemicals, Ambey Laboratories is well-positioned to capitalize on sustained demand.

- Compliance: The company's ISO certification and commitment to environmental compliance align with increasing regulatory standards in the chemical industry, providing a competitive advantage.